Patients (male/female) with proven mutations in BRCA-1 gene (chromosome 17) and/or BRCA-2 (chromosome 13) either with or without manifest tumor disease (ICD10 Z15.01) C50.9
Conditions
Interventions
Group 1: 6 Weeks Intervention.
HIRT + HIT high intensity endurance and resistance training.
HIRT: high intensity resistance training >80% of 1-RM, 8-12 repetitions, 2 sets
2 days per week (combined with and after HIT)
HIT: high intensity endurance training at >90% VO2max, 10 min warm up (50 % VO2max), 10 x 1min > 90% VO2max, 3 min cool down at 50% VO2 max.
3 days per week, two days supervised, one day free training.
Group 2: 6 Weeks Intervention.
LIA - Low Impact Aerobic: stretching, breathing and relaxation exercises. one set 60 min duration, 3 times
Sponsors
Universitätsklinikum Ulm, Vorstand,
Eligibility
Sex/Gender
All
Age
18 Years to 69 Years
Inclusion criteria
Inclusion criteria: verified BRCA mutation, no acute malignant tumor therapy; last medical intervention > 3 months ago, signed consense agreement of participant
Exclusion criteria
Exclusion criteria: additional physical exercise training of both study arms; other diseases preventing to join the exercise program; other factors preventing communication (language barriers or psychological disorders); pregnany of women
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| T2: 2-3 days after the last intervention: 1. Skeletal muscle: gene expression of BRCA1 and BRCA-Protein; Activity of acetyl-CoA-Carboxylase 2. Oxidative Stress: Thiolstatus in Serum | — |
Secondary
| Measure | Time frame |
|---|---|
| T2: 2-3 days after the last intervention: 3. Gene expression of Superoxid-dismutase (SOD2), HSP72, in Skeletal Muscle MaCoA; CPT-1; 4. psychology a. quality of life (QoL SF-36) b. level of sanguinity (LOT-R) 5. anthropometric data (body height, body weight, body fat, waist to height ratio (WtHR) 6. skeletal muscle (muscle mass, sonography of m. vastus medialis; molecular profile of skeletal muscle 7. energy metabolism, mitochondrial function 8. immunology, pro- and antiinflammatory factors (IL-1beta, IL-6, TNF-alpha, IL-10); Kynurenine 9. physical performance (maximal strength 1-RM, endurance (spiroergometry VO2 max) 10. physical activity (accelerometer, actiheart); metabolic rate at rest (indirect calorimetry) 11. heart function with focus on diastolic function and right ventricular and right arterial function, echodardiography 12. lipid metabolism; irisin; oral glucose tolerance test (oGTT) | — |
Countries
Germany
Contacts
Public ContactJürgen Steinacker
Universitätsklinikum Ulm Zentrum für Innere Medizin Sektion Sport- und Rehabilitationsmedizin
Outcome results
None listed